5 completed, 1 recruiting. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 5, Recruiting 1 |
Follow Health Services Needs and Demand: new trials by email Literature Review of Health Services Needs and Demand trials Research Report on Health Services Needs and Demand
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness and Safety of TENS Therapy for Premature Ejaculation Tens therapy, Dapoxetine placebo, Standard treatment (dapoxetine 30 mg as needed) - Premature Ejaculation, Sex Disorder | Phase 3 | Recruiting | Boston Medical Group | 129 | 2022-06-15 | 2024-05-22 |
| A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | GlaxoSmithKline | 828 | 2012-10-15 | 2018-05-02 |
| Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Double-dummy placebo - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | GlaxoSmithKline | 512 | 2011-03-18 | 2018-02-15 |
| A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes. tadalafil once a day [T(OaD)], sildenafil citrate as needed [S(PRN)], tadalafil as needed [T(PRN)] - Erectile Dysfunction | Phase 3 | Completed | Eli Lilly and Company | 378 | 2008-08-01 | 2010-11-18 |
| A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise Dapagliflozin, Dapagliflozin placebo, Metformin - Type 2 Diabetes | Phase 3 | Completed | AstraZeneca | 1067 | 2007-09-01 | 2015-10-20 |
| DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults Symbicort, used twice daily (b.i.d) and as needed (prn), Budesonide Turbuhaler 200 µg, Fluticasone Discus 250 µg - Asthma | Phase 3 | Completed | AstraZeneca | 1600 | 2004-12-01 | 2009-03-17 |
Pulmonary Disease, Chronic Obstructive (2) · Asthma (1) · Diabetes Mellitus, Type 2 (1) · Erectile Dysfunction (1) · Premature Ejaculation (1) · Sexual Dysfunction, Physiological (1)
AstraZeneca (2) · GlaxoSmithKline (2) · Boston Medical Group (1) · Eli Lilly and Company (1)
Germany (4) · United States (4) · Mexico (3) · Italy (2) · Russia (2) · Spain (2) · Ukraine (2) · Australia (1) · Brazil (1) · Canada (1) · Puerto Rico (1) · Romania (1) · South Africa (1) · United Kingdom (1)
Anna Maria Langkilde (1) · Heinrich Worth, MD (1) · Jorge Barba, MD (1)
PMID 24998880, PMID 20566676, PMID 22429760, PMID 25381876, PMID 26894924, PMID 27461213, PMID 38770818